touchMDT Immune checkpoint inhibitors in solid tumours: Optimizing outcomes through multidisciplinary collaboration
A multidisciplinary team of specialists discuss the use of immune checkpoint inhibitor therapy in patients with solid tumours.
Overview & Learning ObjectivesPatient with a solid tumour who is a candidate for immunotherapy

Oncologist and oncology nurse
Watch a medical oncologist and an oncology nurse discuss current and upcoming indications for immune checkpoint inhibitors in patients with solid tumours.
Expert Spotlight
Prof. Ken Kato and Ms Tara Hurley discuss current and upcoming indications for immune checkpoint inhibitors in patients with solid tumours, including key disease-specific considerations when developing individual treatment strategies.
Learn More Back to MDT Hub
Oncologist, oncology nurse and oncology pharmacist
Watch a medical oncologist, an oncology nurse and a clinical oncology pharmacist evaluate strategies for identifying and monitoring common immune-related adverse events associated with immunotherapy.
Expert Spotlight
Prof. Ken Kato, Ms Tara Hurley and Dr Alison Palumbo evaluate strategies for identifying and monitoring common immune-related adverse events associated with immunotherapy, and how the risks of developing immune-related adverse events can be predicted and mitigated.
Learn More Back to MDT Hub
Oncologist, oncology nurse and oncology pharmacist
Watch a medical oncologist, an oncology nurse and a clinical oncology pharmacist discuss current recommendations for managing systemic immune-related adverse events.
Expert Spotlight
Prof. Ken Kato, Ms Tara Hurley and Dr Alison Palumbo discuss current recommendations for managing systemic immune-related adverse events, including considerations for referral to organ specialists.
Learn More Back to MDT Hub
Oncologist and pathologist
Watch a medical oncologist and a pathologist review the role of biomarkers in guiding ICI therapy in patients with solid tumours.
Expert Spotlight
Prof. Ken Kato and Prof. Albrecht Stenzinger review the role of biomarkers in guiding immune checkpoint inhibitor therapy in patients with solid tumours, including associated challenges and limitations, and discuss how effective biomarker testing can be used in clinical practice.
Learn More Back to MDT Hub